1. Scrip
  2. >>Business
  3. >>Earnings

Teva Edges Closer To Growth, But With A Big Overhang

 
• By Jessica Merrill

Teva's turnaround is progressing, but the company forecast largely flat revenues and earnings in 2020. A threat to the improved stability is how an opioid litigation settlement might unfold.

Work in progress warning sign with yellow and black stripes painted over cracked concrete wall coarse texture background. Concept for do not enter the area, caution, danger, construction site.
A Teva turnaround is progressing • Source: Shutterstock

Teva Pharmaceutical Industries Ltd. is heading into the third year of a massive turnaround strategy that began under CEO Kare Schultz in late 2017, and while the company made substantial progress on its goal of returning to earnings growth in 2020, the expectation for generic revenues continues to be moderate and there is a threat to the stability from opioid liability litigation.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Regulatory And Macroeconomic Uncertainty Hang Over Q1 Earnings Season

 
• By Jessica Merrill

As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.

US Pharma Tariff Reprieve Appears Short-Lived

 
• By Jessica Merrill

Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.

Pharma Exhales, Dodging A Financial Blow With Tariff Exemption

 
• By Jessica Merrill

Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.

More from Business

Biotech Leaders Fear FDA Disruption Is Causing Delays

 
• By Jessica Merrill

A letter to US Senate HELP Committee Chair Bill Cassiday sounds an alarm about irreparable damage to the FDA, signed by more than 200 biotech executives and investors.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Q1 VC Financings Fall Short As Early Deals, Mega-Rounds Dip

 
• By Mandy Jackson

Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.